Nomenclature of HBV core protein-targeting antivirals

Fabien Zoulim^#¹, Adam Zlotnick^#², Stephanie Buchholz³, Eric Donaldson⁴, John Fry⁵, Anuj Gaggar⁶, Jianming Hu⁷, Michael Kann^{8

9}, Oliver Lenz¹⁰, Kai Lin¹¹, Nagraj Mani¹², Michael Nassal¹³, William Delaney¹⁴, Su Wang¹⁵, Gabriel Westman¹⁶, Veronica Miller¹⁷, Harry L A Janssen^{18

19}

Affiliations

¹ Hepatology Department, INSERM Unit 1052, Hospices Civils de Lyon, Lyon University, Lyon, France. fabien.zoulim@inserm.fr.
² Molecular and Cellular Biochemistry Department, Indiana University, Bloomington, IN, USA.
³ Federal Institute for Drugs and Medical Devices, BfArM, Bonn, Germany.
⁴ US Food and Drug Administration, Silver Spring, MD, USA.
⁵ Aligos Therapeutics, San Francisco, CA, USA.
⁶ Arrive Bio, San Francisco, CA, USA.
⁷ Department of Microbiology and Immunology, The Pennsylvania State University College of Medicine, Hershey, PA, USA.
⁸ Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
⁹ Department of Clinical Microbiology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
¹⁰ Janssen Pharmaceutica NV, Beerse, Belgium.
¹¹ Aerium Therapeutics, Boston, MA, USA.
¹² Arbutus Biopharma Inc., Department of Biology, Warminster, PA, USA.
¹³ Department of Medicine II, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
¹⁴ Assembly Biosciences, South San Francisco, CA, USA.
¹⁵ Cooperman Barnabas Medical Center, RWJBarnabas-Rutgers Medical Group, Livingston, NJ, USA.
¹⁶ Swedish Medical Products Agency, Uppsala University, Uppsala, Sweden.
¹⁷ The Forum for Collaborative Research, Washington, DC, USA.
¹⁸ Department of Gastroenterology & Hepatology, Erasmus Medical Center, Rotterdam, Netherlands.
¹⁹ Toronto Centre for Liver Disease, University of Toronto, Ontario, Canada.

^# Contributed equally.

PMID: 36207612
PMCID: PMC10442071
DOI: 10.1038/s41575-022-00700-z

Nomenclature of HBV core protein-targeting antivirals

Fabien Zoulim et al. Nat Rev Gastroenterol Hepatol. 2022 Dec.

. 2022 Dec;19(12):748-750.

doi: 10.1038/s41575-022-00700-z.

Authors

Affiliations

¹ Hepatology Department, INSERM Unit 1052, Hospices Civils de Lyon, Lyon University, Lyon, France. fabien.zoulim@inserm.fr.
² Molecular and Cellular Biochemistry Department, Indiana University, Bloomington, IN, USA.
³ Federal Institute for Drugs and Medical Devices, BfArM, Bonn, Germany.
⁴ US Food and Drug Administration, Silver Spring, MD, USA.
⁵ Aligos Therapeutics, San Francisco, CA, USA.
⁶ Arrive Bio, San Francisco, CA, USA.
⁷ Department of Microbiology and Immunology, The Pennsylvania State University College of Medicine, Hershey, PA, USA.
⁸ Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
⁹ Department of Clinical Microbiology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
¹⁰ Janssen Pharmaceutica NV, Beerse, Belgium.
¹¹ Aerium Therapeutics, Boston, MA, USA.
¹² Arbutus Biopharma Inc., Department of Biology, Warminster, PA, USA.
¹³ Department of Medicine II, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
¹⁴ Assembly Biosciences, South San Francisco, CA, USA.
¹⁵ Cooperman Barnabas Medical Center, RWJBarnabas-Rutgers Medical Group, Livingston, NJ, USA.
¹⁶ Swedish Medical Products Agency, Uppsala University, Uppsala, Sweden.
¹⁷ The Forum for Collaborative Research, Washington, DC, USA.
¹⁸ Department of Gastroenterology & Hepatology, Erasmus Medical Center, Rotterdam, Netherlands.
¹⁹ Toronto Centre for Liver Disease, University of Toronto, Ontario, Canada.

^# Contributed equally.

PMID: 36207612
PMCID: PMC10442071
DOI: 10.1038/s41575-022-00700-z

No abstract available

PubMed Disclaimer

Figures

**Figure 1:. mode of action of CAMs supporting the proposed nomenclature**
PDB file is 6BVF. EM is from Kondylis, Schlicksup, et (2020)

See this image and copyright information in PMC

References

1. Venkatakrishnan B & Zlotnick A The Structural Biology of Hepatitis B Virus: Form and Function. Annual Review of Virology 3, 429–451 (2016). - PMC - PubMed
1. Niklasch M, Zimmermann P & Nassal M The Hepatitis B Virus Nucleocapsid—Dynamic Compartment for Infectious Virus Production and New Antiviral Target. Biomedicines 9, 1577 (2021). - PMC - PubMed
1. Luo Y. et al. Identification of hepatitis B virus core protein residues critical for capsid assembly, pgRNA encapsidation and resistance to capsid assembly modulators. Antiviral Res 191, 105080 (2021). - PubMed
1. Schlicksup CJ, Laughlin P, Dunkelbarger S, Wang JCY & Zlotnick A Local Stabilization of Subunit-Subunit Contacts Causes Global Destabilization of Hepatitis B Virus Capsids. ACS Chemical Biology 15, 1708–1717 (2020). - PMC - PubMed
1. Berke JM et al. Antiviral Properties and Mechanism of Action Studies of the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379. Antimicrob Agents Chemother 64, doi:10.1128/AAC.02439-19 (2020). - DOI - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Nomenclature of HBV core protein-targeting antivirals

Affiliations

Nomenclature of HBV core protein-targeting antivirals

Authors

Affiliations

Figures

References

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources